Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 205-208, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lambert-Messerlian, G. M.
Right arrow Articles by Diamandis, E. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lambert-Messerlian, G. M.
Right arrow Articles by Diamandis, E. P.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 1998;44:205-208.)
© 1998 American Association for Clinical Chemistry, Inc.

Enzymes and Protein Markers

Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome

Geralyn M. Lambert-Messerlian1, Jacob A. Canick1, Dimitrios N. Melegos2, and Eleftherios P. Diamandis2,3,a

1 Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Providence, RI 02905.

2 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, M5G 1X5 Canada.

3 Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, M5G 1L5 Canada.
a Address correspondence to this author at: Pathology and Laboratory Medicine, Mount Sinai Hospital, 600 University Ave., Toronto, Ontario, M5G 1X5 Canada. Fax (416) 586-8628; e-mail ediamandis{at}mtsinai.on.ca.

Down syndrome is one of the most common causes of mental retardation in the industrialized world. Prenatal serum screening to identify mothers at risk of carrying a fetus affected with Down syndrome is presently part of routine obstetrical care. Prostate-specific antigen (PSA) concentration was measured in stored second-trimester maternal serum samples from 19 pregnancies affected with fetal Down syndrome and in 95 samples from unaffected pregnancies, with each case matched to five controls for gestational age and duration of frozen sample storage. Concentrations of PSA in Down syndrome pregnancy were significantly higher (case median = 2.28 multiples of the median; P = 0.02) than in unaffected pregnancy. PSA concentrations were not significantly correlated with the current serum screening analytes, alpha-fetoprotein, unconjugated estriol, or human chorionic gonadotropin in either cases or controls. The increased maternal serum PSA concentrations in Down syndrome pregnancy and their relative independence from other markers suggest the possible utility of PSA as a prenatal screening marker for fetal Down syndrome.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
K. Spencer and P. Carpenter
Is Prostate-specific Antigen a Marker for Pregnancies Affected by Down Syndrome?
Clin. Chem., November 1, 1998; 44(11): 2362 - 2365.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.